Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1404&sort=award_amount
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_amount", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=award_amount", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=award_amount", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1403&sort=award_amount" }, "data": [ { "type": "Grant", "id": "9617", "attributes": { "award_id": "2218054", "title": "RII Track-2 FEC: Membrane Purification Platform for Continuous Biomanufacturing of Viral Vectors and Virus-like Particles in Arkansas and Beyond", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Office Of The Director", "EPSCoR RII Track-2 FEC" ], "program_reference_codes": [], "program_officials": [ { "id": 11391, "first_name": "J.D.", "last_name": "Swanson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-01", "end_date": "2024-07-31", "award_amount": 5999758, "principal_investigator": { "id": 25413, "first_name": "Xianghong", "last_name": "Qian", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 22789, "first_name": "Scott M", "last_name": "Husson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 290, "ror": "https://ror.org/037s24f05", "name": "Clemson University", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true } ] }, { "id": 25410, "first_name": "Dibakar", "last_name": "Bhattacharyya", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 25411, "first_name": "Robert R Beitle", "last_name": "Jr.", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 25412, "first_name": "Ranil", "last_name": "Wickramasinghe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 586, "ror": "", "name": "University of Arkansas", "address": "", "city": "", "state": "AR", "zip": "", "country": "United States", "approved": true }, "abstract": "Biologics are large molecule therapeutics and have been used to treat a variety of diseases, including cancer, diabetes, cardiovascular disease, autoimmune disorders, genetic and ophthalmologic diseases to name a few. Biologics include monoclonal antibodies (mAbs) and other therapeutic proteins, vaccines such as mRNA vaccines, cell and gene therapies products such as stem cells, and viral vectors. The impact of biologics on human health has been tremendous with the success of mRNA vaccines for COVID-19 as an example. The market for biologics is increasing exponentially, reaching over $300 billion as of today. The large demand for biologics places great challenge on the manufacturing process. The total cost for downstream process accounts for up to 80% of the total manufacturing cost. The vision of this RII Track-2 FEC project is to create a membrane-based downstream purification platform for the future large scale biomanufacturing of viral vectors and virus-like particles (VLPs) for gene therapy and vaccine applications. This platform will be used to replace the current processes such as centrifugation and resin-based chromatography that are difficult to scale up. The overall goal of this project is to develop innovative and practical unit operations that could be part of a platform for the downstream purification of these virus particle-based therapeutics. The project brings together multidisciplinary researchers with complementary expertise from three EPSCoR jurisdictions from the University of Arkansas (Arkansas), Clemson University (South Carolina) and University of Kentucky (Kentucky). Each of the three institutions offers unique facilities and resources that can rapidly catalyze the technology development. The economic impact of the proposed activities on the entire state of Arkansas as well as on Kentucky and South Carolina will be significant. Regional incubator centers for biotechnology industry of tomorrow will be established in the three EPSCoR states. Successful development of a high-productivity membrane purification platform is expected to improve human health by improving access to revolutionary treatments for genetic and chronic diseases for mid- and low-income families. Workforce development for the future biotechnology industry, a commitment to diversity through collaborations with Minority-serving Institutions, and a focus on early career faculty mentorship are key components of the project. The project will provide internship opportunities for graduate students and research experiences for undergraduates to develop the STEM workforce in this field. In addition, all three universities will outreach to the respective Minority-serving Institutions in the state to foster collaborative research experiences. \n \nDevelopment of cost-effective large scale biomanufacturing for the purification of viral vectors and virus-like particles (VLPs) is a major challenge. Membrane based unit operations are attractive; however, membrane capacity, fouling and lack of commercial membranes as well as the robustness of membrane performance under a range of operating conditions have limited applications by industrial practitioners. This project will address key issues and overcome critical barriers for developing a membrane-based bioprocessing platform for viral vectors and VLPs. The project aims to overcome the technical and economic barriers at multiple fronts and involve close collaborations among researchers at three different institutions in three EPSCoR jurisdictions. More specific research objectives include (1) feedstock production of two common viral vectors for gene therapy applications and VLPs for vaccine applications; (2) advanced microfiltration operations for bioreactor harvesting; (3) high capacity affinity membrane design, fabrication and characterization; (4) downstream membrane chromatography for separating full and empty viral capsids; (5) module design, process optimization and process intensification; (6) employing state-of-the-art bioanalytical methods for detection and quantification; and (7) a technology readiness and acceptance study. Through the project's collaborative research efforts across three universities, researchers will build upon existing infrastructure at each institution, expanding it far beyond current capabilities.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "520", "attributes": { "award_id": "2011846", "title": "Bioinspired Soft Materials", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Mathematical and Physical Sciences (MPS)" ], "program_reference_codes": [], "program_officials": [ { "id": 1072, "first_name": "Miriam", "last_name": "Deutsch", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-01", "end_date": "2026-08-31", "award_amount": 6000000, "principal_investigator": { "id": 1073, "first_name": "Seth", "last_name": "Fraden", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 280, "ror": "https://ror.org/05abbep66", "name": "Brandeis University", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 280, "ror": "https://ror.org/05abbep66", "name": "Brandeis University", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Nontechnical Abstract: The Brandeis Bioinspired Soft Materials Research Science and Engineering Center (MRSEC) seeks to engineer new materials that capture the remarkable functionalities found in living organisms. To realize this vision the Center synergistically focuses on two topics at the forefront of Soft Materials research. The first, Self-Limiting Assembly, adopts a bioinspired approach to develop a suite of building blocks which undergo equilibrium self-assembly that terminates at a prescribed finite-size. Learning to engineer self-limiting structures is enabling the scalable design of new functional and adaptable materials, such as paintable photonic coatings and capsids for drug therapy including general strategies to deactivate virus infection, including covid-19. The second, Soft Active Materials, is inspired by the remarkable capabilities of living cells, with their abilities to sense, self-heal and move. This MRSEC is establishing the principles to design, measure and control the forces in active materials to generate rapidly reconfigurable life-like materials, with applications in fields as diverse as robotics, microfluidics and adaptive optics. The MRSEC emphasizes human resource development for the STEM workforce. To facilitate this is the MRSEC’s SciComm Lab comprising science graduate students and postdocs trained to become effective communicators and peer mentors. These SciComm Lab mentors train their peers in the skills they need to communicate their science to disparate audiences ranging from future employers to a diverse, non-scientific public. The Path-to-Professorship Program, aimed at providing superior postdoctoral fellow training for underrepresented minorities in cutting-edge materials research and designed to prepare individuals for assuming full-time faculty positions.Technical Abstract: The Brandeis Bioinspired Soft Materials Research Science and Engineering Center (MRSEC)is engineering new materials that capture the remarkable functionalities found in living organisms. The Center is organized into two Interdisciplinary Research Groups (IRG). IRG1, Self-Limiting Assembly, addresses a grand challenge in soft materials science, the self-assembly of complex and functional materials. While living systems routinely achieve size-controlled assembly, synthetic approaches lag far behind. IRG1 adopts a bioinspired approach to develop a suite of building blocks which undergo equilibrium self-assembly that self-terminates at a prescribed finite-size. Learning to engineer self-limiting structures is enabling scalable design of new functional and adaptable materials, such as paintable photonic coatings and capsids for drug and gene therapy. IRG2, Soft Active Materials, is inspired by the remarkable capabilities of living cells, such as crawling, reconfiguring, and regenerating which are driven by energy-consuming molecular motors. An unmet grand challenge is to construct artificial active materials with active stresses designed to produce a desired function. This is leading to the next generation of active materials that are robust and exhibit long-lived programmable dynamics, thus paving the way to applications. This MRSEC emphasizes human resource development for the STEM workforce. To facilitate this is the MRSEC's SciComm Lab comprising science graduate students and postdocs trained to become effective communicators and peer mentors. The Path-to-Professorship Program, aimed at providing superior postdoctoral fellow training for underrepresented minorities in cutting-edge materials research and designed to prepare individuals for assuming full-time faculty positions.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "4199", "attributes": { "award_id": "1632810", "title": "RII Track-2 FEC: Sustainable socio-economic, ecological, and technological scenarios for achieving global climate stabilization through negative CO2 emission policies", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Office Of The Director", "EPSCoR Research Infrastructure" ], "program_reference_codes": [], "program_officials": [ { "id": 14145, "first_name": "Eric", "last_name": "Lindquist", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2016-08-01", "end_date": "2022-07-31", "award_amount": 6000000, "principal_investigator": { "id": 14149, "first_name": "Selena", "last_name": "Ahmed", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 259, "ror": "https://ror.org/02w0trx84", "name": "Montana State University", "address": "", "city": "", "state": "MT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 14146, "first_name": "David L", "last_name": "Swanson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 14147, "first_name": "Meghann E", "last_name": "Jarchow", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 14148, "first_name": "Benjamin", "last_name": "Rashford", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 259, "ror": "https://ror.org/02w0trx84", "name": "Montana State University", "address": "", "city": "", "state": "MT", "zip": "", "country": "United States", "approved": true }, "abstract": "Non-technical description\nThis Research Infrastructure Improvement Track-2 Focused EPSCoR Collaboration (RII Track-2 FEC) award is a collaboration among three institutions in Montana, Wyoming, and South Dakota including Montana State University (MSU), University of Wyoming (UW) and University of South Dakota (USD). The project will focus on developing a framework of CO2 mitigation scenarios that would not create conflicts with food security and production of clean energy. The project will offer novel experimental insights, modeling tools, and technological solutions for improving the resiliency of food security and ecosystem services to global climate policies. The modeling activities and extensive field research is expected to generate new data and findings that will lead to new insights into how biogeochemical modeling, agricultural economics, carbon-capture and sequestration, water and biodiversity research can be used within an integrated framework. The project will leverage existing networks and hubs to integrate new data-streams into the modeling exercises. Through involvement with Tribal Colleges and networking with existing programs with Native American student populations, the project will serve to enhance and diversify the STEM workforce in the participating jurisdictions.\n\nTechnical description\nThe proposed project will evaluate the consequences of a bioenergy, and carbon capture and sequestration (BECCS) economy in the Upper Missouri River Basin (UMRB). In seeking to evaluate how negative CO2 emissions, and the security and economic costs associated with changes to energy policy, the project will address four research objectives: (1) Develop empirical and numerical models to explain recent trends in land use and land-cover change; (2) Apply biogeochemical ecosystem and crop models to evaluate a set of stakeholder-designed regions and scenarios for bioenergy production potential, and use new and existing data and observations to quantify trade-offs between biofuel expansion and food security and other carbon, soil and bioclimate variables; (3) Evaluate the feasibility of BECCS within the context of carbon capture and storage, existing political and institutional constraints, and policy frameworks affecting farmers and Tribal Nations; and (4) Produce a synthesis report addressing the economic feasibility of BECCS and provide the basis for knowledge transfer to collaborators at national and international organizations. The collaborations with several government agencies, non-governmental organizations, and the private sector, in addition to a scientific advisory panel, provide high potential that the project and its findings will transfer to national and international stages.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11419", "attributes": { "award_id": "1UM1TR004407-01", "title": "Scripps Clinical and Translational Science Hub", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21379, "first_name": "SOJU", "last_name": "Chang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-05-01", "end_date": "2030-04-30", "award_amount": 6029792, "principal_investigator": { "id": 23339, "first_name": "Eric Jeffrey", "last_name": "Topol", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 745, "ror": "", "name": "SCRIPPS RESEARCH INSTITUTE, THE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 745, "ror": "", "name": "SCRIPPS RESEARCH INSTITUTE, THE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT The Scripps Research Translational Institute (SRTI) is the foundation for the Scripps hub and is dedicated to accelerating science that will improve human health. SRTI’s emphasis on genomics, digital medicine, and informatics/analytics fosters a multi-dimensional understanding of individualized human health. The Scripps hub has previously included the Scripps Research Institute (SR) and Scripps Health (SH) as principal partners, including Rady Children’s Institute of Genomic Medicine (RCIGM) for genomic medicine initiatives and California Institute for Medical Research (Calibr) for drug repurposing / discovery. In the new CTSA cycle, our partners have expanded to include San Diego State University (SDSU), enabling us to combine forces in computer science, artificial intelligence, biosensors, and diversity inclusion and equity initatives. SRTI’s expertise in genomics was highlighted during the pandemic. We became one of the country’s most productive sequencing centers for SARS-CoV-2 by rapidly forming the “SEARCH” alliance to process samples with the San Diego County Department of Health, UCSD, Sharp Health, California Department of Public Health, Helix, and our partners RCIGM and SH. Digital medicine has been one of SRTI’s core strengths, having pioneered the first remote, site-less digital clinical trial and now expanding this methodology to address many other medical conditions such as health during pregnancy and sleep disorders. Our Digital Trials Center launched the Digital Engagement & Tracking for Early Control and Treatment Scripps (DETECT) study, and in a matter of weeks our team was able to accurately predict the likelihood of Covid with SARS-CoV-2 using passively collected resting heart rate data from wristband sensors and later to identify a physiologic signature that correlates with Long Covid (Post-Acute Sequelae or SARS-CoV-2 Infection). The Scripps hub will innovate clinical and translational science to improve human health across the lifespan and diverse racial, ethnic, geographic and socioeconomic communities. The hub will provide a nurturing environment for education, training, and career development with a focus on individualized health domains of genomics, digital medicine, and biomedical informatics, to empower tomorrow’s diverse workforce.", "keywords": [ "2019-nCoV", "Acceleration", "Address", "Area", "Artificial Intelligence", "Awareness", "Biosensor", "California", "Child", "Clinical Research", "Clinical Sciences", "Clinical Trials", "Collaborations", "Communities", "Country", "County", "Data", "Data Aggregation", "Data Set", "Dedications", "Democracy", "Diagnostic", "Dimensions", "Dissemination and Implementation", "Diverse Workforce", "Drug Screening", "Ecosystem", "Education", "Elements", "Ethics", "Ethnic Origin", "Fostering", "Foundations", "Genomic medicine", "Genomics", "Geography", "Goals", "Health", "Healthcare", "Heart Rate", "Human", "Human Resources", "Industry Collaboration", "Informatics", "Institute of Medicine (U.S.)", "Institution", "Intervention", "Longevity", "Medical", "Medical Research", "Methodology", "Modeling", "Outcome", "Patients", "Physiological", "Population", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Preventive", "Process", "Productivity", "Program Development", "Public Health", "Public Health Informatics", "Race", "Research", "Research Institute", "Research Project Grants", "Resource Informatics", "Resources", "Rest", "SARS-CoV-2 infection", "Sampling", "Science", "Services", "Site", "Sleep Disorders", "Structure", "Techniques", "Time", "Training", "Translational Research", "Universities", "Vision", "Voice", "biomedical informatics", "career development", "community engaged research", "community engagement", "computer science", "computerized data processing", "cost effective", "data standards", "digital", "digital medicine", "digital models", "digital twin", "diversity and inclusion", "drug repurposing", "educational atmosphere", "empowerment", "equity diversity and inclusion", "ethnic diversity", "health data", "health equity", "health inequalities", "improved", "individualized medicine", "innovation", "interoperability", "multimodal data", "multimodality", "pandemic disease", "pregnancy disorder", "programs", "public health emergency", "racial diversity", "real time model", "response", "secondary analysis", "sensor", "socioeconomics", "tool", "translational approach" ], "approved": true } }, { "type": "Grant", "id": "8122", "attributes": { "award_id": "75N92021C00009-0-9999-1", "title": "RADX TECH XTRAVA, INC. - SPERA COVID-19 AG TESTRAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT #5834 XTRAVA, INC.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-03-04", "end_date": "2022-03-03", "award_amount": 6207000, "principal_investigator": { "id": 23997, "first_name": "SAMEH", "last_name": "SARHAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Mitigating the economic and health challenges of COVID-19 is hindered by the absence of mass population testing. Available platforms are designed for lab-use and rely on sophisticated technologies and readers. They are slow, expensive, hard to manufacture and overload healthcare professionals with time consuming manual workflows; presenting massive obstacles to high throughput testing. We introduce a novel platform to diagnose COVID-19, which includes a digital test that combines fluorescent lateral flow assays with our patent-pending cost-optimized lateral flow test platform which was initially developed to detect H1N1. We have formed the essential alliances with key partners to rapidly scale up manufacturing and distribution to the points-of-need. Nasal swabs (and soon saliva samples) are tested in under 15 minutes. The digital results are wirelessly communicated to the participants’ mobile devices and the cloud thereby providing healthcare providers with test status and sharing real-time analytics and monitoring capabilities with health authorities. In the first stage, the test will be deployed into CLIA-waived point-of-care clinics, walk-in facilities and drive-thru testing centers for less than $35 for the digital test and with an effective cost of less than $10 per disposable test. After full validation, we will immediately extend deployment to at-home use by leveraging machine vision-guided self-testing. By combining IoT technologies that are proven to enable large-scale production with rapid diagnostic testing we believe we are uniquely positioned to increase testing throughput by 10X-100X. RADx re-enforcement will propel the launch of the system in highly condensed timeframes to meet the enormous need.", "keywords": [ "Acceleration", "COVID-19", "COVID-19 diagnosis", "Clinic", "Consumption", "Diagnostic", "Diagnostic tests", "Economics", "Health", "Health Personnel", "Health Professional", "Home", "Influenza A Virus H1N1 Subtype", "Legal patent", "Manuals", "Monitor", "Population", "Positioning Attribute", "RADx", "RADx Tech", "Rapid diagnostics", "Reader", "System", "Technology", "Testing", "Time", "Validation", "Walking", "Wireless Technology", "authority", "cost", "design", "digital", "handheld mobile device", "large scale production", "lateral flow assay", "machine vision", "manufacturing scale-up", "nasal swab", "novel", "point of care", "programs", "saliva sample", "self testing" ], "approved": true } }, { "type": "Grant", "id": "14897", "attributes": { "award_id": "1U19AI181767-01", "title": "The Michigan Infectious Disease Genomics (MIDGE) Center", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 8282, "first_name": "Inka I", "last_name": "Sastalla", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-06-14", "end_date": "2027-05-31", "award_amount": 6233451, "principal_investigator": { "id": 31584, "first_name": "Adam", "last_name": "Lauring", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31585, "first_name": "Evan", "last_name": "Snitkin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "– Overall The advent of genomic sequencing technologies has revolutionized our understanding of disease transmission, pathogen evolution, drug resistance, and virulence. Pathogens can quickly adapt to new environments and treatments, making it critical to understand the underlying genetic changes that drive this process. The proposed Michigan Infectious Disease Genomics (MIDGE) Center will feature four projects, each focused on a group of pathogens, unified by a common theme of identifying pathogen determinants of epidemic success and by a common approach that combines genomic surveillance, functional genomics, and high-throughput phenotyping assays. Project 1 examines the genomic determinants of epidemic success in SARS-CoV-2, RSV, and influenza viruses. Here, epidemic success is linked to the virus’s ability to transmit and spread within an immune population through mutations that either increase intrinsic transmissibility or allow for escape from neutralizing antibodies. Project 2 investigates the impact of genetic background on the emergence and spread of carbapenem-resistant Enterobacteriales, where epidemic success is linked not only to drug resistance genes and mutations but also to the genetic background on which they arise. Project 3 will define genetic and genomic determinants of colonization in Candida auris, an emerging fungal pathogen. The key to the epidemic success of C. auris appears to be its remarkable ability to adhere to and colonize the skin and the built environment, and this project will leverage whole genome sequencing, microbial GWAS, and functional genomic screens to identify the genetic circuitry for this trait. Project 4 uses functional genomic approaches to understand the virulence of epidemic strains of Toxoplasma gondii, which are more common in South America and cause a distinct disease from that associated with other globally dispersed lineages. Genomic surveillance of scat from wild cats will be used to further define the diversity of potentially epidemic, hypervirulent strains in this region. A Technical and Data Core will support the work of all four projects with staff bioinformaticians and research data analysts as well as Investigators with expertise in phylogenetics, high-throughput phenotyping assays, and analysis of complex data sets. The Administrative Core will leverage local strengths in training and outreach and provide an infrastructure for regulatory compliance, financial reporting, and data and resource sharing. Through successful execution of this research plan, the MIDGE Center will develop genomic methods and protocols to study infectious diseases and will advance genomics more broadly in basic and clinical research across viral, bacterial, fungal, and parasitic pathogens.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9318", "attributes": { "award_id": "75N93020C00055-0-9999-1", "title": "DEVELOPMENT OF THERAPEUTIC PRODUCTS FOR COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-01", "end_date": "2021-06-30", "award_amount": 6326480, "principal_investigator": { "id": 25063, "first_name": "WILLIAM", "last_name": "SHERIDAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1808, "ror": "", "name": "BIOCRYST PHARMACEUTICALS, INC.", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1808, "ror": "", "name": "BIOCRYST PHARMACEUTICALS, INC.", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the advanced development of a promising candidate therapeutic for NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.", "keywords": [ "Advanced Development", "COVID-19", "Categories", "Chemistry", "Clinical", "Coronavirus", "Development", "Emerging Communicable Diseases", "National Institute of Allergy and Infectious Disease", "Pathway interactions", "Safety", "pre-clinical", "priority pathogen", "product development", "research and development", "therapeutic candidate", "therapeutic development" ], "approved": true } }, { "type": "Grant", "id": "8838", "attributes": { "award_id": "1U01GH002346-01", "title": "GH21-003, Advancing Public Health Research in Kenya", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-30", "end_date": "2026-09-29", "award_amount": 6329348, "principal_investigator": { "id": 24649, "first_name": "M KARIUKI", "last_name": "NJENGA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 306, "ror": "https://ror.org/05dk0ce17", "name": "Washington State University", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 306, "ror": "https://ror.org/05dk0ce17", "name": "Washington State University", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "(ADMINISTRATIVE CORE) Our Consortium consisting of Washington State University (WSU), the Liverpool School of Tropical Medicine (LSTM), and the Kenya Medical Research Institute (KEMRI) proposes to support KEMRI to develop and manage a highly cost-effective and sustainable KEMRI/CGHR Research Platform (KRP) in western Kenya (under “Category 1. Research Coordination and Administration” of the administrative core). The platform includes the population-based health and demographic surveillance systems, laboratories in Kisumu and Nairobi, clinical research centers in Kisumu, and offices and shared services at the Kisian campus, Kisumu. Between 2014 and 2020, KRP’s day-to-day management was changed three times to make it more efficient, transparent, affordable, and less contentious with KEMRI, CDC, and other partners. Currently, the platform is managed by KEMRI, with CDC (through its partners) contributing financially together with the other international partners who share the platform. WSU and LSTM have an excellent relationship with KEMRI and its partners and many years of administrative and technical expertise in Kenya. Following extensive discussions and agreements leading up to this joint application, WSU, LSTM, and KEMRI central leadership will support KEMRI/CGHR to implement a management plan to strengthen the Center’s capacity to assume cost-effective and sustainable management of the platform in support of their public health research in Kenya. This will include a phased introduction of financial and administrative management systems, mutually agreed systems for cost-sharing across all national and international partners sharing the facilities, close fiscal oversight by WSU, and mentorship and training. KEMRI has already taken critical steps to streamline the platform’s management and strengthen its leadership, including the appointment of three senior staff at KEMRI/CGHR, the revision of policies to enhance decision-making at the Center level, and commitment to providing its share of financial support. It also includes the rolling out of an electronic system for the management of grant and ethics applications. As part of “Category 2. Research Laboratory Administration”, we will maintain accreditation standards, quality assurance processes, and integrated biosafety and biosecurity systems to support KEMRI state-of-the-art laboratories. We will also introduce a laboratory information management system, including for effective management of samples and associated data. The KEMRI laboratories recently demonstrated their utility to the country by providing >70% of the country’s testing capacity for COVID-19 pandemic. In addition, we present evident technical expertise to lead the Research Core areas identified in the RFA, including HIV and TB, malaria, influenza, and other respiratory pathogens, zoonotic diseases, antimicrobial resistance, neglected tropical diseases, non-communicable diseases, and vaccine- preventable diseases. Experienced WSU and LSTM scientists will team up with KEMRI and CDC counterparts to design, implement, and publish research, an approach designed to train and mentor KEMRI scientists in applying and managing research funding. In the accompanying Research Core proposals, these teams describe field and laboratory activities that address each required outcome and objective of the RFA. Table 5 of this Administrative Core provides a work plan showing how each study will be implemented over the program’s 5-year duration.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "1042", "attributes": { "award_id": "2042875", "title": "PSID 2021-2024: Continuity and Change in American Economic and Social Life", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Social, Behavioral, and Economic Sciences (SBE)" ], "program_reference_codes": [], "program_officials": [ { "id": 2563, "first_name": "Nancy", "last_name": "Lutz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-07-15", "end_date": "2025-06-30", "award_amount": 6344210, "principal_investigator": { "id": 2565, "first_name": "Katherine", "last_name": "McGonagle", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 169, "ror": "", "name": "Regents of the University of Michigan - Ann Arbor", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 2564, "first_name": "Narayan", "last_name": "Sastry", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 169, "ror": "", "name": "Regents of the University of Michigan - Ann Arbor", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "The Panel Study of Income Dynamics (PSID) is a cornerstone of data infrastructure for social science research in the United States. The study has used a series of surveys to gather information on US families since 1968. Children and grandchildren from the original PSID families now participate as well; the result is data that follows families through several generations. The long timespan allows scientific investigation of questions about how people and families grow and change over time. This includes the study of economic outcomes such as employment, income, and wealth, research on how early life experiences affect employment and health in adulthood, research on how U.S. families cope with the needs of aging family members, and work that examines how key economic variables like consumption and employment are affected by broader businesses cycles and unanticipated events. The research team will collect two new waves of data. The new waves will include measurements of the effects of the COVID-19 pandemic on PSID families. This includes measurements of the direct health impacts of the disease, the effects of disruptions to employment and education, and whether family members were helped by government efforts to reduce the burden of the pandemic. The PIs also plan new measurements of participation in short term ‘gig economy’ jobs, will expand valuable administrative data linkages, and will continue their current effort to expand web-based administration of the PSID questionnaire. The project promotes the national interest by maintaining U.S. leadership in science, by making data available to a broad community of researchers interested in understanding American families, and by providing necessary data to evaluate the long-term impacts of past policy decisions at the federal, state, and local levels of government.The PSID is the world's longest running household panel survey. Through its long-term measures of economic and social wellbeing, the study allows researchers and policy analysts to investigate the dynamism inherent in social and behavioral process. The long panel, genealogical design, and broad content provide scientists a unique and powerful opportunity to study change within the same family over decades. Collecting additional waves of data from the PSID families contributes to scientific understanding of the dynamics of economic and social behavior. The extended time series of data supports new and systematic investigation of a myriad of questions in the full range of scientific disciplines that study how humans grow and change over the life cycle. This includes the study of economic outcomes (for example, the changes that occur across business cycles and changes in response to increased international economic competition), the study of intergenerational transmission of wealth and income, and the study of how income and health in adulthood and old age depend on early-life experiences. Consistent measures over time are important for accurately estimating the dynamics of these behaviors. Gathering data from the same families over many years improves the precision of the measurement as multiple measures are collected within the same families as well as from multiple families over a period of decades. The investigators will carry out numerous innovations and enhancements while maintaining core data collection for comparability. The PSID creates broader impacts in many ways. It is used by an interdisciplinary community and is increasingly important in health research. The data archive is used to inform public policy; at least nine federal agencies use PSID data. The PSID is also an important resource for teaching and learning. The data are free and publicly available. They are widely used by graduate and undergraduate students. The award funds web-based outreach activities that will make the PSID an even more valuable tool for teaching and learning.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "12363", "attributes": { "award_id": "1OT2OD036430-01", "title": "All of Us Research Program Heartland Consortium (AoURP-HC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 28291, "first_name": "IRENE", "last_name": "PRABHUDAS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2024-08-31", "award_amount": 6349986, "principal_investigator": { "id": 28292, "first_name": "Gillian", "last_name": "Bartlett-Esquilant", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 7997, "first_name": "Akinlolu Oluseun", "last_name": "Ojo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23563, "first_name": "K ALLEN", "last_name": "GREINER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28293, "first_name": "ALEJANDRO Pierre", "last_name": "COMELLAS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28294, "first_name": "Cyrus V", "last_name": "Desouza", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28295, "first_name": "Tammy", "last_name": "Peterman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28296, "first_name": "Matthias A", "last_name": "Salathe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28297, "first_name": "Steven W", "last_name": "Stites", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 875, "ror": "https://ror.org/036c9yv20", "name": "University of Kansas Medical Center", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true }, "abstract": "Racial and ethnic minorities and residents of rural communities (rural residents) experience the greatest health disparities. Health disparities, as defined by the World Health Organization, are plausibly avoidable differences in health outcomes closely linked with social, economic, and environmental disadvantages. Health disparities, which cost the U.S. economy more $1 trillion annually, are worsened by underrepresentation in biomedical research (UBR). The National Academy of Medicine, the Food and Drug Administration (FDA), and other authoritative bodies have issued reports and are promoting strategies to increase the participation of racial/ethnic minorities, rural residents, and other UBR populations in biomedical research as a necessary step to mitigate health disparities. To wit, this proposal aims to increase the participation of racial/ethnic minorities and rural residents in the largest precision medicine initiative in history by incorporating the All of Us Research Program Heartland Consortium (AoURP-HC) as a Healthcare Provider Organization (HPO) into the National Institutes of Health's (NIH) All of Us Research Program (AoURP). The AoURP-HC is a partnership of academic medical centers, hospitals, and community organizations in the central United States that will work together to enroll Kansas, Missouri, Nebraska, and Iowa residents into the most ambitious precision medicine initiative in history. The AoURP-HC will engage with the NIH's AoURP to further the goal of enrolling one million individuals who reflect the diversity of the United States, focusing on racial/ethnic minority groups and rural residents who are historically among the most UBR. The disproportionate and calamitous impact of COVID-19 on racial/ethnic minority groups and rural residents lends urgency to efforts to enrich the AoURP with UBR populations. Our team, while on the pandemic frontlines, observed the geographic and race/ethnicity-based disparities in the impact of COVID-19. For example, Gove County, Kansas, had the highest COVID-19 death rate in the US, and the rural town of Quinter, Iowa, lost 1 in 132 residents to COVID-19, compared to the national average of 1 in 10,000 deaths.1 Race/ethnicity emerged as a significant determinant of COVID-19-related deaths in the US (after age 75 years³), with more than three-fold differences in adjusted mortality rates (per 100,000) among different racial/ethnic groups. This disproportionate COVID-19 morbidity and mortality in UBR populations, underpinned by genetic, physiologic, environmental, occupational, and lifestyle factors, will be better elucidated by the AoURP. The AoURP-HC aims to address the underrepresentation of the central U.S. in the AoURP by establishing a formal partnership among four academic medical centers, along with their affiliated hospitals and clinics. The proposed collaboration will pursue four objectives: (1) we deploy a metrics-driven campaign will aim to enroll >30,000 full participants in five years of whom 50% will be racial ethnic/minority groups and rural residents; (2) we will send electronic health records periodically by means of secured and standardized AoURP IT processes and procedures to the Data and Research Center; (3) we will work collaboratively with the national AoURP infrastructure, including HPOs, the Biobank, and the Consortium Steering Committee, to develop and implement AoURP research protocols; and (4) we will abide by AoURP policies, maintain fidelity to the AoURP core values, and actively participate in AoURP ancillary studies, task forces, and working groups. Pursuant to these objectives, we will implement a comprehensive participant engagement and retention plan that values the participants as partners and convene a Participant Advisory Board to design and implement program activities. Our targeted enrollment of UBR populations into the AoURP will enhance the geographic and ethnic diversity of the All of Us cohort, enhance public participation in precision medicine research, and help to ensure the benefits of targeted therapies and personalized preventative strategies reach rural populations.", "keywords": [ "Academic Medical Centers", "Academy", "Acute Renal Failure with Renal Papillary Necrosis", "Address", "Advisory Committees", "Age", "All of Us Research Program", "Alzheimer&apos", "s Disease", "Ancillary Study", "Asthma", "Biomedical Research", "Black Populations", "COVID-19", "COVID-19 disparity", "COVID-19 impact", "COVID-19 morbidity", "COVID-19 mortality", "COVID-19 pandemic", "COVID-19 prevention", "Cardiovascular Diseases", "Cessation of life", "Clinics and Hospitals", "Collaborations", "Communities", "County", "Data", "Death Rate", "Disadvantaged", "Disease", "Economics", "Electronic Health Record", "Enrollment", "Ensure", "Ethnic Origin", "Ethnic Population", "Genetic", "Geography", "Goals", "Health", "Health Personnel", "Health system", "Hospitalization", "Individual", "Infrastructure", "Iowa", "Kansas", "Link", "Longevity", "Malignant Neoplasms", "Maternal and Child Health", "Measures", "Medical center", "Medicine", "Mental Health", "Minority Groups", "Mission", "Missouri", "Myocarditis", "Nebraska", "Not Hispanic or Latino", "Occupational", "Outcome", "Participant", "Physiological", "Policies", "Population", "Precision Medicine Initiative", "Predisposition", "Prevention strategy", "Procedures", "Process", "Protocols documentation", "Public Participation", "Quality Control", "Quality of Care", "Quality of life", "Race", "Recording of previous events", "Reduce health disparities", "Reporting", "Research", "Research Project Grants", "Research Proposals", "Resources", "Rural", "Rural Community", "Rural Population", "Secure", "Standardization", "Substance abuse problem", "Technical Expertise", "Therapeutic Clinical Trial", "United States", "United States Food and Drug Administration", "United States National Institutes of Health", "Universities", "Wit", "Work", "World Health Organization", "biobank", "cohort", "community organizations", "cost", "data exchange", "data warehouse", "design", "disorder prevention", "ethnic disparity", "ethnic diversity", "ethnic minority", "ethnic minority population", "experience", "geographic disparity", "health difference", "health disparity", "hospital organization", "improved", "innovation", "institutional capacity", "lifestyle factors", "mortality", "pandemic disease", "participant enrollment", "participant retention", "patient engagement", "precision medicine", "prevention clinical trial", "programs" ], "approved": true } } ], "meta": { "pagination": { "page": 1404, "pages": 1424, "count": 14236 } } }